Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses.
This well done meta-analysis by recognized experts in the field helps allay some of the concerns generated by articles that published negative outcomes for cancer patients receiving ESAs when the ESAs were given outside recommended guidelines. Further, the guidelines that were present when these (negative) papers were published were far less restrictive than those in effect today. The authors are to be congratulated for their excellent work in this well written, easy to read, informative paper.
– Michael Auerbach